ALB and intracerebral hemorrhage: However, the ALIAS (albumin in AIS) part 1 and 2 trials and the combined data analyses showed that intravenous infusion of 25% human serum albumin (2 g/kg) was not associated with improved outcome at 90 days and was associated with the increased incidence of intracerebral hemorrhage and pulmonary edema (Martin et al., 2016).